alprenolol has been researched along with Asthma in 10 studies
Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.
alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used mice with no detectable systemic adrenaline (PNMT(-/-) ) and wild-type (WT) mice to study the effects of four β-blockers, alprenolol, carvedilol, propranolol and nadolol, in an ovalbumin sensitization and challenge (Ova S/C) murine model of asthma." | 3.81 | β-Blockers have differential effects on the murine asthma phenotype. ( Bond, RA; Bouvier, M; Forkuo, GS; Joshi, R; Knoll, BJ; Leff, P; Parra, S; Thanawala, VJ; Valdez, DJ, 2015) |
| " Chronic administration of alprenolol, a beta-blocker without inverse agonist properties, did not attenuate the asthma phenotype, suggesting that it is signaling by empty receptors, rather than agonist-induced beta(2)-AR signaling, that supports the asthma phenotype." | 1.35 | Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. ( Bond, RA; Dickey, BF; Hanania, NA; Knoll, BJ; Lin, R; Nguyen, LP; Omoluabi, O; Parra, S; Tuvim, MJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thanawala, VJ | 1 |
| Valdez, DJ | 1 |
| Joshi, R | 1 |
| Forkuo, GS | 1 |
| Parra, S | 2 |
| Knoll, BJ | 2 |
| Bouvier, M | 1 |
| Leff, P | 1 |
| Bond, RA | 2 |
| Nguyen, LP | 1 |
| Lin, R | 1 |
| Omoluabi, O | 1 |
| Hanania, NA | 1 |
| Tuvim, MJ | 1 |
| Dickey, BF | 1 |
| Stiles, GL | 1 |
| Caron, MG | 1 |
| Lefkowitz, RJ | 1 |
| Galant, SP | 1 |
| Duriseti, L | 1 |
| Underwood, S | 1 |
| Insel, PA | 1 |
| Brooks, SM | 2 |
| McGowan, K | 2 |
| Altenau, P | 2 |
| Bernstein, IL | 1 |
| Peagler, J | 1 |
| Ablad, B | 1 |
| Carlsson, E | 1 |
| Ek, L | 1 |
| Gross, F | 1 |
| Beumer, HM | 1 |
| Simpson, FO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma[NCT00670267] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bronchoprovocation assessment was done by doubling doses of methacholine in accordance with the methodology recommended by the American Thoracic Society in the official policy statement adopted by the ATS Board of Directors, July 1999 (Guidelines for Methacholine and Exercise Challenge Testing-1999). (NCT00670267)
Timeframe: Baseline to end of study (105 days)
| Intervention | mg/mL (Mean) |
|---|---|
| Open Label Treatment With Oral Nadolol | 1.8 |
In the E.F. Juniper Asthma Control Questionnaire, a lower number reflects better control of asthma symptoms. A positive change in ACQ score reflects a reduction in control compared to baseline; conversely, a negative change in ACQ score reflects an increase in control compared to baseline. The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). Clinic staff score the FEV1% predicted on a 7-point scale. The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). (NCT00670267)
Timeframe: Baseline to end of study (105 days)
| Intervention | units on a scale (Mean) |
|---|---|
| Open Label Treatment With Oral Nadolol | 0.3 |
The outcome measure describes the mean daily dose achieved by the subjects at study termination. This data includes one subject who terminated early, having reached 2.5mgs and subsequently reducing to 1.25mgs prior to dropping out. (NCT00670267)
Timeframe: Baseline to end of study (105 days)
| Intervention | mg (Mean) |
|---|---|
| Open Label Treatment With Oral Nadolol | 29.6 |
(NCT00670267)
Timeframe: Baseline to end of study (105 days)
| Intervention | percent change in FEV1% predicted (Mean) |
|---|---|
| Open Label Treatment With Oral Nadolol | -5.9 |
The outcome measure describes the final daily dose achieved by the subjects in this study. The subjects described below who finished on less than the highest dose (i.e., 1.25, 5, and 10mgs) had all been down-titrated one dose (i.e., from 2.5, 10, and 20mgs) prior to completing the study on the dose reported. (NCT00670267)
Timeframe: Baseline to end of study (105 days)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| 1.25mgs | 2.5mgs | 5.0mgs | 10.0mgs | 20mgs | 40mgs | |
| Open Label Treatment With Oral Nadolol | 1 | 0 | 1 | 1 | 0 | 7 |
3 reviews available for alprenolol and Asthma
| Article | Year |
|---|---|
Beta-adrenergic receptors: biochemical mechanisms of physiological regulation.
Topics: Adenylyl Cyclases; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; A | 1984 |
Adverse effects of beta-adrenergic receptor blocking drugs on respiratory function.
Topics: Adrenergic beta-Antagonists; Alprenolol; Asthma; Bronchi; Bronchial Spasm; Humans; Isoproterenol; Mu | 1974 |
Beta-adrenergic receptor blocking drugs in hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alprenolol; Antidepressive Agents; Antihy | 1974 |
7 other studies available for alprenolol and Asthma
| Article | Year |
|---|---|
β-Blockers have differential effects on the murine asthma phenotype.
Topics: Adrenergic beta-Antagonists; Allergens; Alprenolol; Animals; Asthma; Bronchoalveolar Lavage Fluid; C | 2015 |
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.
Topics: Alprenolol; Animals; Asthma; Bronchoconstrictor Agents; Disease Models, Animal; Epithelial Cells; Hu | 2009 |
Decreased beta-adrenergic receptors on polymorphonuclear leukocytes after adrenergic therapy.
Topics: Adrenergic beta-Agonists; Alprenolol; Asthma; Humans; In Vitro Techniques; Neutrophils; Receptors, A | 1978 |
Relationship between beta-adrenergic binding in lymphocyte and severity of disease in asthma.
Topics: Adult; Alprenolol; Asthma; Cell Membrane; Cells, Cultured; Culture Media; Female; Humans; Hydrocorti | 1979 |
Relationship between numbers of beta adrenergic receptors in lymphocytes and disease severity in asthma.
Topics: Adult; Alprenolol; Asthma; Binding Sites; Female; Forced Expiratory Volume; Humans; Lymphocytes; Mal | 1979 |
Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists.
Topics: Acetanilides; Adrenergic beta-Antagonists; Alprenolol; Amino Alcohols; Animals; Asthma; Blood Pressu | 1973 |
[Current drugs. Therapy using -blockaders ( -adrenolytics)].
Topics: Acetanilides; Adrenergic beta-Antagonists; Alprenolol; Amino Alcohols; Angina Pectoris; Arrhythmias, | 1973 |